Humira sales growth
Executive Summary
Sales of the TNF inhibitor grew 40 percent in the third quarter to $427 mil. in the U.S. compared to the year-ago period, Abbott reports. Humira (adalimumab), which recently underwent a successful launch for Crohn's disease, also gained share in the rheumatology, dermatology and gastroenterology markets (1"The Pink Sheet" July 23, 2007, p. 11). Worldwide Humira sales were $803 mil. in the quarter, up 48.5 percent from 2006, leading the company to predict 2007 sales of $3 bil. for Abbott's leading product. Overall, Abbott reports a 22.2 percent increase in global pharmaceutical sales and U.S. pharmaceutical sales rose 17.5 percent in the quarter...
You may also be interested in...
Abbott Cardiovascular Franchise Swells; Combo Waves Will Crest in 2009
Abbott plans to submit a fixed-dose statin-fenofibrate combination with AstraZeneca's Crestor in 2009, the company reported during a June 18 sales and earnings call
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.